Patents by Inventor Oskari KARJALAINEN

Oskari KARJALAINEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydrochloride salt forms of a sulfonamide structured kinase inhibitor
    Patent number: 11866420
    Abstract: The present invention relates to novel hydrochloride salt forms of N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 9, 2024
    Assignee: Aurigene Oncology Limited
    Inventors: David Jonaitis, Oskari Karjalainen
  • METHOD FOR PRODUCING NITROFURANTOIN ANHYDRATE, AND PRODUCT THEREOF
    Publication number: 20230212156
    Abstract: The present disclosure relates to a novel process for production of crystalline particles of nitrofurantoin anhydrate, the crystalline particles of nitrofurantoin anhydrate being obtained by a process as disclosed, and pharmaceutical compositions as disclosed including crystalline particles of nitrofurantoin anhydrate.
    Type: Application
    Filed: May 11, 2021
    Publication date: July 6, 2023
    Applicant: FERMION OY
    Inventors: Oskari KARJALAINEN, Mikko LESKINEN
  • METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF
    Publication number: 20230174517
    Abstract: The present invention relates to an improved process for the preparation of 2-chloro-4-(1-tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)benzonitrile (III) which is useful as an intermediate in preparation of carboxamide structured androgen receptor antagonists. The process comprises preparation of compound (III) using heterogeneous palladium catalyst.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 8, 2023
    Inventors: Arne GRUMANN, Oskari KARJALAINEN
  • Process for the preparation of a sulfonamide structured kinase inhibitor
    Patent number: 11332460
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 17, 2022
    Assignee: ORION CORPORATION
    Inventors: Oskari Karjalainen, Pekka Pietikäinen
  • NOVEL HYDROCHLORIDE SALT FORMS OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR
    Publication number: 20210332028
    Abstract: The present invention relates to novel hydrochloride salt forms of N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Application
    Filed: September 5, 2019
    Publication date: October 28, 2021
    Inventors: David JONAITIS, Oskari KARJALAINEN
  • PROCESS FOR THE PREPARATION OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR
    Publication number: 20210139462
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 13, 2021
    Inventors: Oskari KARJALAINEN, Pekka PIETIKÄINEN
  • Process for the preparation of a sulfonamide structured kinase inhibitor
    Patent number: 10870637
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: December 22, 2020
    Assignee: ORION CORPORATION
    Inventors: Oskari Karjalainen, Pekka Pietikäinen
  • PROCESS FOR THE PREPARATION OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR
    Publication number: 20200102291
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 2, 2020
    Inventors: Oskari KARJALAINEN, Pekka PIETIKÄINEN
  • Process for the preparation of androgen receptor antagonists and intermediates thereof
    Patent number: 10189789
    Abstract: The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (AR) antagonists such as N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: January 29, 2019
    Assignee: Orion Corporation
    Inventors: Ilpo Laitinen, Oskari Karjalainen
  • PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF
    Publication number: 20180099938
    Abstract: The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (AR) antagonists such as N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.
    Type: Application
    Filed: April 8, 2016
    Publication date: April 12, 2018
    Inventors: Ilpo LAITINEN, Oskari KARJALAINEN